A Study of Multiple-Antigen Specific Cellular Therapy in Vitro Combined with PD-1 Antibody Technology (MASCT-I) in Patients with Advanced Solid Tumors

X. Zhang,D. Weng,J. Xia,R. Xu

DOI: https://doi.org/10.1093/annonc/mdx666.002

IF: 51.769

2017-01-01

Annals of Oncology

Abstract:Background: Tumor-specific immune responses are known to be initiated by dendritic cells (DCs) that can effectively process and present tumor antigens to CD4+ and CD8+ T cells, eliciting anti-tumor immune responses. MASCT-I technology is a sequential immune cell therapy for cancer treatment, which involves multiple antigen-loaded DC vaccines followed by the adoptive transfer of anti-tumor effector T cells. Patient autologous PBMC-derived DCs are in vitro loaded with multiple tumor antigen peptides to acquire DC vaccines. A part of DC vaccines are injected into patients to induce anti-tumor immunity in vivo. The other part of DCs is co-cultured with autologous PBMCs to induce tumor-specific effector T cells in vitro. During the co-culture, anti-PD1 antibody is included to block immunosuppressive PD1 signal, which can robustly boost anti-tumor efficacy of T cells. Obtained tumor-specific effector T cells are then infused into the patient to further inhibit tumor growth. Trial design: This is a single center, sequential three stages phase I study. 3 + 3 design is used for stage 1 and 2. Stage1 will enroll patients with advanced (unresectable) or recurrent bladder cancer or soft tissue sarcoma who have failed all standard therapies, Patients will be treated with MASCT-I. If the DLT in the first cycle of MASCT-I is < 33.3%, the stage 2 will begin. Patients who have advanced recurrent or metastatic bladder cancer with GP chemotherapy achieving clinical benefit (group 1) will be treated with MASCT-I as maintenance therapy. Also, patients who have advanced recurrent or metastatic sarcoma with achieving clinical benefit after MAID or CAV/IE (predominant Doxorubicin regiments) (group 2) will be treated with MASCT-I combined with Ifosfamide as maintenance therapy too. During the stage 2, if, in the first cycle of MASCT-I treatment, the DLT is < 33.3%, stage 2 will extend to stage 3. Approximately additional 24 patients will be enrolled in group 1 and 2. The primary objective is safety and tolerability. Secondary objectives include DCR, PFS, TTP, OS. Stage 1 was completed on 17 May 2017, recruitment is ongoing for stage 2. Clinical trial indentification: NCT03034304. Legal entity responsible for the study: HRYZ Biotech Co. Funding: HRYZ Biotech Co. Disclosure: All authors have declared no conflicts of interest.